Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of KA-301 for acute spinal cord injury
jRCT2043230067Phase 2Recruiting
- Sponsor
- Kaneka
- Start
- Aug 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KA-301 in spinal cord injury (SCI), sponsored by Kaneka. Primary endpoints: General safety and Change in ASIA motor score from Day 1 to Week 24. Started Aug 2023; status: recruiting.
02
Drugs
KA-301
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on jRCT2043230067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043230067.